Affimed Therapeutics AG, a Heidelberg, Germany-based developer of antibody therapeutics, has raised EUR 25 million in Series B funding. Participants included BioMedInvest, OrbiMed Advisors, Life Sciences Partners and return backer FirstVentury. The company's two lead clinical programs focus on the treatment of Hodgkin's disease and Non-Hodgkin's Lymphoma, respectively. www.affimed.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.